To screen for colorectal cancer, faecal immunochemical tests (FIT) are utilized. Patients aged 60-74 years in England and 50-74 years in Scotland receive screening kits every 2 years. If the test results are abnormal, the patient is provided with the option of undergoing a colonoscopy.

Colorectal Cancer Screening: Faecal Immunochemical Test (FIT)

Colorectal cancer is often developed from adenomatous polyps. Screening for this type of cancer has been proven to reduce mortality by 16%. The NHS offers a home-based screening programme called Faecal Immunochemical Test (FIT) to older adults. A one-off flexible sigmoidoscopy was trialled in England for people aged 55 years, but it was abandoned in 2021 due to the inability to recruit enough clinical endoscopists, which was exacerbated by the COVID-19 pandemic. The trial, partly funded by Cancer Research UK, showed promising early results, and it remains to be seen whether flexible sigmoidoscopy will be used as part of a future bowel screening programme.

Faecal Immunochemical Test (FIT) Screening:
The NHS now has a national screening programme that offers screening every two years to all men and women aged 60 to 74 years in England and 50 to 74 years in Scotland. Patients aged over 74 years may request screening. Eligible patients are sent FIT tests through the post. FIT is a type of faecal occult blood (FOB) test that uses antibodies that specifically recognise human haemoglobin (Hb). It is used to detect and quantify the amount of human blood in a single stool sample. FIT has advantages over conventional FOB tests because it only detects human haemoglobin, as opposed to animal haemoglobin ingested through diet. Only one faecal sample is needed compared to the 2-3 for conventional FOB tests. While a numerical value is generated, this is not reported to the patient or GP. Instead, they will be informed if the test is normal or abnormal. Patients with abnormal results are offered a colonoscopy. At colonoscopy, approximately 5 out of 10 patients will have a normal exam, 4 out of 10 patients will be found to have polyps that may be removed due to their premalignant potential, and 1 out of 10 patients will be found to have cancer.

Biliary colic is a common symptom of gallstones, occurring in 1-4% of patients with choledocholithiasis. The pain is intense and dull, usually resolving within 30-90 minutes, and often occurs after consuming fatty meals. This matches the patient’s symptoms and risk factors. If left untreated, biliary colic can progress to acute cholecystitis, which presents with upper abdominal pain, nausea, vomiting, and fever. However, since the patient’s symptoms resolved within 24 hours, acute cholecystitis is unlikely. Acute viral hepatitis is also an unlikely diagnosis, as the patient has no known exposure to the viruses and her symptoms resolved too quickly. Acute pancreatitis presents with severe abdominal pain, nausea, vomiting, and fever, which does not match the patient’s symptoms. Ascending cholangitis is also unlikely, as the patient is afebrile and not jaundiced, and her symptoms resolved within 24 hours.

The urea breath test is a non-invasive, highly specific and sensitive method. Therefore, there is no need for an endoscopy. Instead, an alternative option is to use stool antigen instead of culture.

Tests for Helicobacter pylori

There are several tests available to diagnose Helicobacter pylori infection. One of the most common tests is the urea breath test, where patients consume a drink containing carbon isotope 13 (13C) enriched urea. The urea is broken down by H. pylori urease, and after 30 minutes, the patient exhales into a glass tube. Mass spectrometry analysis calculates the amount of 13C CO2, which indicates the presence of H. pylori. However, this test should not be performed within four weeks of treatment with an antibacterial or within two weeks of an antisecretory drug.

Another test is the rapid urease test, also known as the CLO test. This involves mixing a biopsy sample with urea and a pH indicator. If there is a color change, it indicates the presence of H. pylori urease activity. Serum antibody tests can also be used, but they remain positive even after eradication. Culture of gastric biopsy can provide information on antibiotic sensitivity, while histological evaluation alone can be done through gastric biopsy. Lastly, the stool antigen test has a sensitivity of 90% and specificity of 95%.

Overall, these tests have varying levels of sensitivity and specificity, and the choice of test depends on the patient’s clinical presentation and the availability of resources.

For patients with non-alcoholic fatty liver disease who exhibit characteristics such as obesity and type 2 diabetes mellitus, it is recommended to conduct an enhanced liver fibrosis (ELF) test to aid in the diagnosis of liver fibrosis. According to NICE guidelines, if NAFLD is discovered incidentally, an ELF blood test should be conducted to evaluate for the presence of more advanced liver disease.

Non-Alcoholic Fatty Liver Disease: Causes, Features, and Management

Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver disease in developed countries, primarily caused by obesity. It encompasses a range of conditions, from simple steatosis (fat accumulation in the liver) to steatohepatitis (fat with inflammation) and may progress to fibrosis and liver cirrhosis. Insulin resistance is believed to be the primary mechanism leading to steatosis, making NAFLD a hepatic manifestation of metabolic syndrome. Non-alcoholic steatohepatitis (NASH) is a type of liver damage similar to alcoholic hepatitis but occurs in the absence of alcohol abuse. It affects around 3-4% of the general population and may be responsible for some cases of cryptogenic cirrhosis.

NAFLD is usually asymptomatic, but hepatomegaly, increased echogenicity on ultrasound, and elevated ALT levels are common features. The enhanced liver fibrosis (ELF) blood test is recommended by NICE to check for advanced fibrosis in patients with incidental NAFLD. If the ELF blood test is not available, non-invasive tests such as the FIB4 score or NAFLD fibrosis score, in combination with a FibroScan, may be used to assess the severity of fibrosis. Patients with advanced fibrosis should be referred to a liver specialist for further evaluation, which may include a liver biopsy to stage the disease more accurately.

The mainstay of NAFLD treatment is lifestyle changes, particularly weight loss, and monitoring. Research is ongoing into the role of gastric banding and insulin-sensitizing drugs such as metformin and pioglitazone. While there is no evidence to support screening for NAFLD in adults, NICE guidelines recommend the management of incidental NAFLD findings.

Elevated serum amylase levels are not always indicative of acute pancreatitis, as they can also be seen in cases of small bowel obstruction. In this scenario, the patient is experiencing abdominal pain, vomiting, and a lack of bowel movements or gas, which are all typical symptoms of small bowel obstruction. The fact that the patient has a history of abdominal surgery further supports this diagnosis, despite the misleading blood test results. Acute cholecystitis, on the other hand, presents with different symptoms such as fever, right upper quadrant pain, and systemic distress, and does not typically cause elevated amylase levels. Acute pancreatitis may also be considered as a differential diagnosis, but it is not associated with a lack of bowel movements or gas, and previous bowel surgery is not a risk factor. Ascending cholangitis and large bowel obstruction can also be ruled out based on the patient’s symptoms and test results.

Small bowel obstruction occurs when the small intestines are blocked, preventing the passage of food, fluids, and gas. The most common cause of this condition is adhesions, which can develop after previous surgeries, followed by hernias. Symptoms of small bowel obstruction include diffuse, central abdominal pain, nausea and vomiting (often bilious), constipation, and abdominal distension. Tinkling bowel sounds may also be present in early stages of obstruction. Abdominal x-ray is typically the first-line imaging for suspected small bowel obstruction, showing distended small bowel loops with fluid levels. CT is more sensitive and considered the definitive investigation, particularly in early obstruction. Management involves initial steps such as NBM, IV fluids, and nasogastric tube with free drainage. Some patients may respond to conservative management, but others may require surgery.

Understanding Coeliac Disease: Symptoms, Diagnosis, and Treatment

Coeliac disease (CD) is a common autoimmune disorder that affects almost 1% of individuals in developed countries. It is triggered by gluten and related prolamins present in wheat, rye, and barley, and primarily affects the small intestine, leading to flattening of the small intestinal mucosa. CD can present in various ways, including typical GI symptoms, atypical symptoms, or no symptoms at all. Diagnosis is made through serology tests for specific autoimmune markers, and treatment involves a lifelong avoidance of gluten ingestion.

Other potential diagnoses, such as travellers’ diarrhoea, growth hormone deficiency, hypothyroidism, and severe combined immunodeficiency, have different clinical presentations and are not consistent with this patient’s symptoms. Understanding the symptoms, diagnosis, and treatment of CD is crucial for proper management and improved quality of life for affected individuals.

Antibiotic therapy is the appropriate course of action to reduce mortality in cirrhotic patients experiencing gastrointestinal bleeding. Prophylactic antibiotics, particularly quinolones, should be administered alongside terlipressin for individuals suspected of having variceal bleeding. The use of cimetidine is not recommended for acute treatment before endoscopy, but it may be used as a preventative measure for mild acid reflux symptoms. Octreotide is sometimes used as an alternative to terlipressin, but studies indicate that it is less effective in reducing mortality. Propranolol is utilized as a prophylactic measure to decrease the incidence of variceal bleeding.

Variceal haemorrhage is a serious condition that requires prompt management. The initial treatment involves resuscitation of the patient before endoscopy. Correcting clotting with FFP and vitamin K is important, as is the use of vasoactive agents such as terlipressin or octreotide. Prophylactic IV antibiotics are also recommended to reduce mortality in patients with liver cirrhosis. Endoscopic variceal band ligation is the preferred method of treatment, and the use of a Sengstaken-Blakemore tube or Transjugular Intrahepatic Portosystemic Shunt (TIPSS) may be necessary if bleeding cannot be controlled. Propranolol and EVL are effective in preventing rebleeding and mortality, and are recommended by NICE guidelines. Proton pump inhibitor cover is given to prevent EVL-induced ulceration.

Understanding Primary Sclerosing Cholangitis

Primary sclerosing cholangitis is a condition that affects the bile ducts, causing inflammation and fibrosis. The cause of this disease is unknown, but it is often associated with ulcerative colitis, with 4% of UC patients having PSC and 80% of PSC patients having UC. Crohn’s disease and HIV are also less common associations. Symptoms of PSC include cholestasis, jaundice, pruritus, right upper quadrant pain, and fatigue. Diagnosis is typically made through endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP), which show multiple biliary strictures giving a ‘beaded’ appearance. A liver biopsy may also be performed, but it has a limited role in diagnosis. Complications of PSC include cholangiocarcinoma in 10% of cases and an increased risk of colorectal cancer.

Overall, understanding primary sclerosing cholangitis is important for early diagnosis and management of the disease. With proper treatment and monitoring, patients can manage their symptoms and reduce the risk of complications.

If a patient has an enlarged gallbladder that is not tender and is accompanied by painless jaundice, it is unlikely to be caused by gallstones. Instead, it is important to consider the possibility of malignancy. Therefore, further investigation should be done to check for malignancy of the gallbladder or pancreas, as either of these conditions could lead to biliary obstruction, resulting in a mass and jaundice.

Exclusion of underlying malignancy or inflammatory bowel disease is necessary as weight loss is not a characteristic of IBS.

Diagnosis and Management of Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects many people. In 2008, the National Institute for Health and Care Excellence (NICE) published clinical guidelines on the diagnosis and management of IBS. According to these guidelines, a positive diagnosis of IBS should be considered if the patient has had abdominal pain, bloating, or a change in bowel habit for at least six months. Additionally, a positive diagnosis should be made if the patient has abdominal pain relieved by defecation or associated with altered bowel frequency stool form, in addition to two of the following four symptoms: altered stool passage, abdominal bloating, symptoms made worse by eating, and passage of mucus. Other features such as lethargy, nausea, backache, and bladder symptoms may also support the diagnosis.

It is important to note that red flag features should be enquired about, including rectal bleeding, unexplained/unintentional weight loss, family history of bowel or ovarian cancer, and onset after 60 years of age. Primary care investigations such as a full blood count, ESR/CRP, and coeliac disease screen (tissue transglutaminase antibodies) are suggested. By following these guidelines, healthcare professionals can effectively diagnose and manage IBS in their patients.